Related Experiment Video
Updated: Nov 18, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Melanoma models for the next generation of therapies
E Elizabeth Patton1, Kristen L Mueller2, David J Adams3
1MRC Human Genetics Unit and Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.
Abstract:
There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.
Insights
Developing better melanoma models is crucial for testing new therapies. This review covers current models and challenges to improve preclinical testing for melanoma treatment.
Area of Science:
- Oncology
- Translational Medicine
- Biomedical Research
Background:
- Effective melanoma models are lacking for evaluating novel therapeutic strategies.
- Current models include genetically engineered mouse, patient-derived xenograft, zebrafish, ex vivo, and in vitro systems.
Purpose of the Study:
- To review the state-of-the-art in melanoma models.
- To identify challenges in melanoma research addressable by these models.
- To provide recommendations for improving preclinical melanoma model accuracy.
Main Methods:
- Comprehensive review of existing literature on melanoma models.
- Analysis of current challenges in melanoma progression and treatment resistance.
- Discussion of unmet needs, such as models for rare melanoma subtypes.
Main Results:
- Identified key challenges: metastasis, tumor dormancy, drug resistance, immune response, and environmental factors.
- Highlighted the need for models for rare melanoma subtypes.
- Outlined opportunities for enhancing model utility in preclinical research.
Conclusions:
- Improved melanoma models are essential for accurate preclinical testing.
- Recommendations focus on enhancing model predictivity for clinical trial efficacy.
- Advancing melanoma models will facilitate the development of next-generation therapies.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...